Arkolith/Insider Trading/AMLX/Form 4

Klee Justin B.

Co-Chief Executive Officer, DirectorAmylyx Pharmaceuticals, Inc. (AMLX) · full profile →Form 4 · filed Nov 6, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 4, 2024Option exercise(M)64K$1.57$100K3.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 4, 2024Option exercise(M)64K—$036K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-122640) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML